Literatur
- 1
Gilbertson D T, Liu J, Xue J L. et al .
Projecting the number of patients with end-stage renal disease in the United States
to the year 2015.
J Am Soc Nephrol.
2005;
16
3736-3741
- 2
Fried L F, Katz R, Sarnak M J. et al .
Kidney function as a predictor of noncardiovascular mortality.
J Am Soc Nephrol.
2005;
16
3728-3735
- 3
Fellstrom B, Jardine A G, Soveri I. et al .
Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal
transplantation: experience from the Assessment of Lescol in Renal Transplantation
trial.
Transplantation.
2005;
79
1160-1163
- 4
Floege J.
Vertrautes in neuem Licht und neue Erkenntnisse aus der Molekular- und Zellbiologie.
Dtsch Med Wochenschr.
2005;
130
1552-1554
- 5
Levey A S, Eckardt K U, Tsukamoto Y. et al .
Definition and classification of chronic kidney disease: a position statement from
Kidney Disease: Improving Global Outcomes (KDIGO).
Kidney Int.
2005;
67
2089-2100
- 6
Shlipak M G, Sarnak M J, Katz R. et al .
Cystatin C and the risk of death and cardiovascular events among elderly persons.
N Engl J Med.
2005;
352
2049-2060
- 7
Pohl M A, Blumenthal S, Cordonnier D J. et al .
Independent and additive impact of blood pressure control and angiotensin II receptor
blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical
implications and limitations.
J Am Soc Nephrol.
2005;
16
3027-3037
- 8
Liu Y, Coresh J, Eustace J A. et al .
Association between cholesterol level and mortality in dialysis patients: role of
inflammation and malnutrition.
Jama.
2004;
291
451-459
- 9
Tonelli M, Keech A, Shepherd J. et al .
Effect of pravastatin in people with diabetes and chronic kidney disease.
J Am Soc Nephrol.
2005;
16
3748-3754
- 10
Wanner C, Krane V, Marz W. et al .
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
N Engl J Med.
2005;
353
238-248
- 11
Fliser D, Kronenberg F, Kielstein J T. et al .
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to
moderate kidney disease study.
J Am Soc Nephrol.
2005;
16
2456-2461
- 12
Bohlender J M, Franke S, Stein G, Wolf G.
Advanced glycation end products and the kidney.
Am J Physiol Renal Physiol.
2005;
289
F645-659
- 13
Tonelli M, Sacks F, Pfeffer M, Jhangri G S, Curhan G.
Biomarkers of inflammation and progression of chronic kidney disease.
Kidney Int.
2005;
68
237-245
- 14
Derchi L E, Leoncini G, Parodi D. et al .
Mild renal dysfunction and renal vascular resistance in primary hypertension.
Am J Hypertens.
2005;
18
966-971
- 15
Gosse P, Safar M E.
Arterial stiffness and plasma creatinine in untreated hypertensive patients.
Am J Hypertens.
2005;
18
1140-1145
- 16
Merjanian R, Budoff M, Adler S. et al .
Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals
with type 2 diabetes and renal disease.
Kidney Int.
2003;
64
263-271
- 17
Ketteler M, Schlieper G, Floege J.
Calcification and Cardiovascular Health: New Insights Into an Old Phenomenon.
Hypertension.
2006;
47
1027-1034
- 18
Ketteler M, Floege J.
Calcification and the usual suspect phosphate: still guilty but there are other guys
behind the scenes.
Nephrol Dial Transplant.
2006;
21
33-35
- 19
Kestenbaum B, Sampson J N, Rudser K D. et al .
Serum phosphate levels and mortality risk among people with chronic kidney disease.
J Am Soc Nephrol.
2005;
16
520-528
- 20
Teng M, Wolf M, Ofsthun M N. et al .
Activated injectable vitamin D and hemodialysis survival: a historical cohort study.
J Am Soc Nephrol.
2005;
16
1115-1125
- 21
Asselbergs F W, Diercks G F, Hillege H L. et al .
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Circulation.
2004;
110
2809-2816
- 22
Haller H, Viberti G C, Mimran A. et al .
Preventing microalbuminuria in patients with diabetes: rationale and design of the
Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
J Hypertens.
2006;
24
403-408
- 23
Hou F F, Zhang X, Zhang G H. et al .
Efficacy and safety of benazepril for advanced chronic renal insufficiency.
N Engl J Med.
2006;
354
131-140
- 24
Winkelmayer W C, Fischer M A, Schneeweiss S. et al .
Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients
with diabetes.
Am J Kidney Dis.
2005;
46
1080-1087
- 25
Ruggenenti P, Perna A, Loriga G. et al .
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal
disease (REIN-2): multicentre, randomised controlled trial.
Lancet.
2005;
365
939-946
- 26
Casas J P, Chua W, Loukogeorgakis S. et al .
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs
on renal outcomes: systematic review and meta-analysis.
Lancet.
2005;
366
2026-2033
- 27
Nakao N, Yoshimura A, Morita H. et al .
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme
inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.
Lancet.
2003;
361
117-124
- 28
Aranda P, Segura J, Ruilope L M. et al .
Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive
nondiabetic nephropathies.
Am J Kidney Dis.
2005;
46
1074-1079
- 29
Schmieder R E, Klingbeil A U, Fleischmann E H, Veelken R, Delles C.
Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized,
prospective study.
J Am Soc Nephrol.
2005;
16
3038-3045
- 30
Fiebeler A, Nussberger J, Shagdarsuren E. et al .
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
Circulation.
2005;
111
3087-3094
- 31
Pilz B, Shagdarsuren E, Wellner M. et al .
Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic
rats.
Hypertension.
2005;
46
569-576
- 32
Cunningham J, Danese M, Olson K, Klassen P, Chertow G M.
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and
health-related quality of life in secondary hyperparathyroidism.
Kidney Int.
2005;
68
1793-1800
- 33
Lauschke A, Teichgraber U K, Frei U, Eckardt K U.
‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure.
Kidney Int.
2006;
69
1669-1674
- 34
Anders H J, Banas B, Schlondorff D.
Signaling danger: toll-like receptors and their potential roles in kidney disease.
J Am Soc Nephrol.
2004;
15
854-867
- 35
Ostendorf T, Rong S, Boor P. et al .
Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental
glomerulonephritis.
J Am Soc Nephrol.
2006;
17
1054-1062
- 36
Eckardt K U, Bernhardt W M, Weidemann A. et al .
Role of hypoxia in the pathogenesis of renal disease.
Kidney Int Suppl.
2005;
99
S46-S51
- 37
Panzer U, Steinmetz O M, Stahl R A, Wolf G.
Kidney diseases and chemokines.
Curr Drug Targets.
2006;
7
65-80
- 38
Janssen B, Hohenadel D, Brinkkoetter P. et al .
Carnosine as a protective factor in diabetic nephropathy: association with a leucine
repeat of the carnosinase gene CNDP1.
Diabetes.
2005;
54
2320-2327
- 39
Benzing T, Walz G.
Cilium-generated signaling: a cellular GPS?.
Curr Opin Nephrol Hypertens.
2006;
15
245-249
- 40
Panzer U, Schneider A, Steinmetz O M. et al .
The chemokine receptor 5 Delta32 mutation is associated with increased renal survival
in patients with IgA nephropathy.
Kidney Int.
2005;
67
75-81
- 41
Eitner F, Floege J.
Therapeutic targets for prevention and regression of progressive fibrosing renal diseases.
Curr Opin Investig Drugs.
2005;
6
255-261
- 42
Gaedeke J, Neumayer H H, Peters H.
Pharmacological management of renal fibrotic disease.
Expert Opin Pharmacother.
2006;
7
377-386
- 43
Haubitz M, Wittke S, Weissinger E M. et al .
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy.
Kidney Int.
2005;
67
2313-2320
- 44
Yu D, Petermann A, Kunter U. et al .
Urinary podocyte loss is a more specific marker of ongoing glomerular damage than
proteinuria.
J Am Soc Nephrol.
2005;
16
1733-1741
- 45
Dragun D, Muller D N, Brasen J H. et al .
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
N Engl J Med.
2005;
352
558-569
- 46
Poggio E D, Wang X, Greene T, Van Lente F, Hall P M.
Performance of the modification of diet in renal disease and Cockcroft-Gault equations
in the estimation of GFR in health and in chronic kidney disease.
J Am Soc Nephrol.
2005;
16
459-466
Prof. Dr. med. Jürgen Floege
Medizinische Klinik II, Universitätsklinikum der RWTH Aachen
Pauwelsstraße 30
52057 Aachen
Phone: 0049/241/8089530
Fax: 0049/241/8082446
Email: Juergen.Floege@rwth-aachen.de
